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Abstract
Background: Vascular fibrinolytic balance is maintained primarily by interplay of tissue plasminogen activator (t-PA) and
plasminogen activator inhibitor type 1 (PAI-1). Previous research has shown that polymorphisms in genes from the renin-
angiotensin (RA), bradykinin, and fibrinolytic systems affect plasma concentrations of both t-PA and PAI-1 through a set of
gene-gene interactions. In the present study, we extend this finding by exploring the effects of polymorphisms in genes
from these systems on incident cardiovascular disease, explicitly examining two-way interactions in a large population-
based study.
Methodology/Principal Findings: Data from the population-based PREVEND study in Groningen, The Netherlands
(n=8,138) were analyzed. The effects of the polymorphisms and their interactions on cardiovascular events were analyzed
via Cox proportional hazards models. There was no association between five of the six polymorphisms singly and risk of
cardiovascular disease. There was a significant main effect for the ACE I/D polymorphism for both dominant and additive
coding schemes. There were significant interactions between the following polymorphism pairs even after adjustment for
known risk factors: ACE I/D & PAI-1 4G/5G (p=0.012), BDKRB2 C181T & ACE I/D (p=0.016), BDKRB2 C58T & ACE I/D (p=0.025),
BDKRB2 exon 1 I/D & AT1R A1166C (p=0.017), and BDKRB2 C58T & AT1R A1166C (p=0.015).
Conclusions/Significance: This study suggests possible interactions between genes from the RA, bradykinin, and fibrinolytic
systems on the risk of cardiovascular disease, extending previous research that has demonstrated that interactions among
genes from these systems influence plasma concentrations of both t-PA and PAI-1. Further explorations of these
interactions are needed.
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Introduction
Both tissue plasminogen activator (t-PA) and plasminogen
activator inhibitor type 1 (PAI-1) are involved in thrombus
formation and degradation. Vascular fibrinolytic balance is
determined by the competing effects of t-PA and PAI-1 [1]. Factors
that increase PAI-1 levels and decrease t-PA levels may increase the
riskof thrombosis asboth arerisk markers forcardiovascular disease
[2,3]. There is substantial evidence that both the renin-angiotensin
(RA) and bradykinin system play a role in the regulation of PAI-1
and t-PA. Previous research has shown that infusion of angiotensin
II increases PAI-1 levels in both hypertensive and normotensive
patients [4]. In addition, ACE-inhibitors significantly decrease PAI-
1 activity in patients with a myocardial infarction [5], in
hypertensive subjects [6], and in postmenopausal women [7].
Bradykinin is a potent stimulator of t-PA in the coronary circulation
and this effect was augmented by ACE-inhibition [8]. In addition,
we previously demonstrated that levels of PAI-1 and t-PA in a
population-based sample are partly determined by genetic poly-
morphisms from the RA and bradykinin systems [9]. Furthermore,
we found significant interactions between polymorphisms from the
renin-angiotensin (RA), bradykinin, and fibrinolytic systems on the
plasma concentrations of t-PA and PAI-1 in two independent
studies [10,11].
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12757Given their role with respect to regulating vascular fibrinolytic
balance, it is possible that variations in polymorphisms in genes
from these systems may ultimately influence the risk of
cardiovascular disease. Some, but not all, studies have shown
such associations [12–15]. Discrepant results for each individual
polymorphism may be the result of interactions with another gene
or genes, i.e., each genetic variation may be associated with
cardiovascular risk only in the presence of certain other genetic
variation. Such gene-gene interactions may occur in the absence of
independent main effects. Thus, it is possible that interactions
among genes from these three systems might modify the effect of
these genes on the risk of cardiovascular disease. Studies often
have limited power to explore gene-gene interactions necessitating
the use of large datasets. Given this and the biologic plausibility of
epistatic effects of polymorphism in genes from the RA,
bradykinin, and fibrinolytic systems, the purpose of the present
exploratory study was to examine the effects of two-way
interactions among these polymorphisms on incident cardiovas-
cular disease in a large, population-based study.
Methods
Study design and participants
Data analyzed in this study were obtained from the Prevention
of Renal and Vascular End-stage Disease (PREVEND) study. The
PREVEND study is a large observational study currently
underway in the city of Groningen, the Netherlands (started in
1997–1998). The PREVEND cohort consists of a random sample
of subjects with less than 10 mg/L of urinary albumin and a
selected sample of subjects with greater than 10 mg/L of urinary
albumin. A total of 8,592 subjects completed the total screening
program and were followed over time. Details of the study have
been described previously [16]. The original study was approved
by a local medical ethics committee and all participants gave
written informed consent.
The combined endpoint for the present analysis was incident
cardiovascular disease, defined as death from CVD (ICD-10 I00-
I02, I05-I15, I20-I28, I30-I52, I60-I89, I95-I99), hospitalization
for MI (ICD-10 I21, I22), percutaneous transluminal angioplasty
(PCTA), or coronary artery bypass graft (CABG). The first well-
defined cardiovascular event of each participant was used for
analysis. Event-free survival time for each participant was defined
as the period from the date of the outpatient clinic baseline
assessment to the date of death, MI, PCTA, or CABG or death
from any cause or until December 31, 2005, the latest date on
which information regarding specific causes of death follow-up
information was available.
Only subjects with a negative history of coronary artery disease
(CAD) at baseline were included in the present analysis. Previous
documented CAD was defined as history of myocardial infarction,
revascularization procedure, or obstructive coronary artery disease
prior to inclusion in the PREVEND study. A history of myocardial
infarction was based on subjects’ medical history, including a
structured questionnaire, and information on previous CAD was
complemented by review of the medical report. This approach has
been used by other published reports from the PREVEND study
[17]. Of the 8,592 PREVEND subjects, 453 were excluded for this
reason, and one additional subject was excluded due to a missing
value on the selection variable (i.e., urinary albumin concentra-
tion), leaving an analysis sample of 8,138.
Demographic and clinical information was collected for each
participant at baseline. In addition, genotyping was conducted on
six polymorphisms as described by Asselbergs et al. [11]. These
polymorphisms (with rs numbers), classified by system, can be
found in Table 1. Genotype information was unavailable for a
number of participants. For example, the largest number of
missing cases is for the ACE I/D polymorphism (missing 674
subjects or 8.3% of the analysis sample). About 89% of the subjects
had complete data on all six polymorphisms (n=7,260). To
evaluate the potential impact of missing genotype information, six
new variables were created to identify cases that had missing data
on each of the polymorphisms and another variable to indicate
whether a case was missing data on any of the polymorphisms
(composite variable). Times to first well-defined cardiovascular
event between subjects with missing data and without missing data
on each of the six polymorphisms (and the composite variable)
were compared using Kaplan-Meier estimates. None of the log-
rank tests revealed significantly different survival curves (df=1,
P.0.50 for each of the tests). Based on these findings, for each
subsequent analysis, a complete-case approach was utilized (i.e.,
participants who were missing genotype information were
excluded). A similar approach was used by Borggreve et al. [18].
Statistical analysis
SAS 9.1 (SAS Institute, Cary, NC, USA) and STATA SE 9.1
(StataCorp LP, College Station, TX, USA) were used for data
analysis. The effects of the polymorphisms on cardiovascular
events were analyzed via Cox proportional hazards models. The
proportional hazards assumption for the polymorphisms and
potential confounders (i.e., demographic and clinical variables)
were assessed by graphing log-log survival functions and by
evaluation interactions between each variable with time. These
examinations suggested that there were no substantial violations of
the proportional hazards assumption.
In the screening phase of the PREVEND study, subjects with an
elevated UAE were over-sampled to acquire sufficient subjects
with microalbuminuria (n=5,661 with UAC $10 mg/L and
n=2,477 with UAC ,10 mg/L at baseline in the present analysis
sample). To overcome this selection bias in the present study,
design-based analyses were performed using sampling probability
weights. Due to this weighting method, our conclusions can be
generalized for the general population [19]. Previously published
reports from the PREVEND study have implemented similar
design-based analyses [20,21]. The design-based Cox regression
models were built with STATA.
As an initial step, the unadjusted, unmoderated effects of each
polymorphism were examined. Prior to this analysis, all genotypes
were coded (AA=0, Aa=1, aa=2) to capture additive effects,
(AA=0, Aa or aa=1) to capture dominant effects, and (AA or
Aa=0,aa=1) to capture recessive effects (where AA=homozygous
wild-type, Aa=heterozygous, and aa=homozygous variant; see
Table 1 for the correspondence of AA, Aa, and aa to each genotype
for each polymorphism).
The second step was to analyze unadjusted, two-way interaction
effects for the 15 possible pairs of polymorphisms. For each pair,
nine possible interaction effects were tested (additive by additive,
additive by dominant, additive by recessive, dominant by additive,
dominant by dominant, dominant by recessive, recessive by
additive, recessive by dominant, and recessive by recessive). We
used an uncorrected significance level of a=0.10 as suggestive
evidence for interaction and a more conservative significance level
of a=0.025 as strong evidence for interaction. A similar approach
was used by Asselbergs et al. [11] who argue that given the
exploratory and early-stage nature of their work, they were more
concerned with false negatives (type II errors) than false positives
(type I errors). A comparable argument can be made for the
present hypothesis-generating study. For readers wishing to use
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supporting information tables S1a-S1f.
The third step of the analysis was to adjust the estimates by
including the following demographic and clinical variables
collected at baseline: sex, age, body mass index, presence of
diabetes, systolic and diastolic blood pressure, HDL cholesterol,
total cholesterol, c-reactive protein, current smoking status, and
waist-to-hip ratio. Prior to interpretation, for pairs of polymor-
phisms where there were multiple significant interactions (e.g.,
additive-additive and dominant-recessive), we selected the model
that provided the most parsimonious fit to the data using Akaike’s
information criterion (AIC) from the covariate-adjusted model.
Finally, because there is some evidence that the prediction of
plasma t-PA/PAI-1 levels by these polymorphisms may differ by
sex [9] and that the relationship between plasma concentrations of
t-PA/PAI-1 and cardiovascular disease-related traits may also
differ by sex [22], we evaluated whether the significant interactions
differed by sex by fitting three-way interactions (sex x genotype1 x
genotype2) in both the unadjusted and adjusted models.
Results
Baseline demographic and clinical characteristics of the sample
can be found in Table 1. Groups with small numbers of cases can
lead to large parameter estimates and standard errors (i.e.,
instability of model fitting) in Cox regression. The frequency for
the homozygous variant genotype for the BDKRB2 C181T
polymorphism (TT) was rare (1.3%). Therefore, neither recessive
coding (i.e., TT versus CT + CC) nor additive coding (i.e., CC
versus CT versus TT) were used for this polymorphism in any
analysis. The symbol ‘‘N/A’’ reflects these models in subsequent
tables.
Table 1. Baseline characteristics of study population (n=8,138).
Characteristic Subcategory Mean (SD) or %
Age (n=8,138) 48.6 (12.5)
Body mass index (kg/m
2) (n=8,050) 26.0 (4.2)
Presence of diabetes (n=7,981) 3.4%
Systolic blood pressure (mmHg) (n=8,134) 128.7 (20.2)
Diastolic blood pressure (mmHg) (n=8,134) 73.9 (9.8)
HDL cholesterol (mmol/L) (n=7,940) 1.3 (0.4)
Total cholesterol (mmol/L) (n=8,072) 5.6 (1.1)
C-reactive protein (mg/L) (n=7,721) 2.6 (4.9)
Current smoking status (n=8,109) 38.1%
Waist-hip ratio (n=8,052) 0.88 (0.09)
Sex (n=8,138) Male 48.9%
Female 51.1%
Bradykinin system
Bradykinin receptor B2 C181T CC (AA) 80.0%
(BDKRB2 C181T) (rs1046248) (n=7,873) CT (Aa) 18.7%
TT (aa) 1.3%
Bradykinin receptor B2 C58T CC (AA) 33.1%
(BDKRB2 C58T) (rs1799722) (n=7,880) CT (Aa) 48.2%
TT (aa) 18.8%
Bradykinin receptor B2 exon 1 insertion/deletion 29/29 (AA) 28.6%
(BDKRB2 exon 1 I/D)
1 (n=7,796) 29/+9 (Aa) 50.7%
+9/+9 (aa) 20.7%
Renin-angiotensin system
Angiotensin II receptor type I A1166C AA (AA) 50.1%
(AT1R A1166C) (rs5186) (n=7,740) AC (Aa) 41.1%
CC (aa) 8.8%
Angiotensin converting enzyme insertion/deletion ACE II (AA) 24.8%
(ACE I/D) (rs4646994) (n=7,464) ACE ID (Aa) 48.3%
ACE DD (aa) 26.9%
Fibrinolytic system
Plasminogen activator inhibitor-1 4G5G 5G5G (AA) 21.6%
(PAI-1 4G/5G) (rs1799768) (n=7,774) 4G5G (Aa) 49.1%
4G4G (aa) 29.3%
1The BDKRB2 exon 1 polymorphism was done with primers flanking the 9 basepair insertion/deletion site, 59-FAM-AGCCCTTGAAAGATGAGCTGT as forward primer and
59-CTCTGTGCTGGGACAGTTTG as reversed primer, resulting in 222 and 213 basepair products for the insertion or deletion allele, respectively.
doi:10.1371/journal.pone.0012757.t001
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years), a total of n=463 events were detected among the 8,138
subjects in the dataset (5.7%). Table 2 presents results of the
analysis of the unadjusted, unmoderated effects of each polymor-
phism for each coding scheme. Five of the six polymorphisms
showed non-significant effects. However, the main effect for the
ACE I/D polymorphism was significant at the 0.05 level for the
dominant (HR=0.72, 95% CI: 0.52–0.99, P=0.042) as well as
the additive coding scheme (HR=0.79, 95% CI: 0.65–0.98,
P=0.029). The findings suggest a smaller hazard associated with
the presence of each ACE D allele (i.e., moving from 0 (ACE II
genotype) to 1 (ACE ID genotype) to 2 (ACE DD genotype)). This
effect is opposite of what one would expect to find based on
previous research. The ACE DD genotype has been found to be
associated with increased levels of PAI-1 in some [23], but not all
[24], studies and also increased levels of angiotensin-converting
enzyme (ACE) [25]. High levels of both PAI-I and ACE promote
thrombosis.
We found evidence for RAS-fibrinolytic and bradykinin-RAS
interaction effects on incident CVD (P values for the statistical tests
for unadjusted two-way interactions among the polymorphisms
are provided supporting information tables S1a-S1f. Significant
results with strong or suggestive evidence for interaction are in
bold). A total of 6 gene-gene interactions were detected out of 15
possible pairs of polymorphisms. Of the 9 possible interactions for
the combination of ACE I/D and PAI-1 4G/5G, 8 were significant
(the ACE I/D x PAI-1 4G/5G (recessive-dominant) was the only
non-significant interaction for this pair).
A summary of the 16 gene-gene interactions with strong or
suggestive evidence can be found in Table 3 along with the
covariate-adjusted results. The model with the lowest AIC among
covariate-adjusted models within each pair of polymorphisms is
noted. For one of the interactions (i.e., AT1R A1166C x PAI-1 4G/
5G), it appears that adjusting for known risk factors attenuates the
suggestive significance observed in the unadjusted analysis
(unadjusted P=0.026, adjusted P=0.151). Hence, this interaction
is not further explored. Statistical significance was maintained for
the other five interactions following adjustment for potential
confounders.
The subgroup effects of the five remaining gene-gene interac-
tions are further explored in Table 4. The BDKRB2 C58T x ACE
I/D interaction shows non-significant subgroup effects in the
unadjusted model and one significant subgroup effect only after
adjustment for covariates. Given these findings and the explor-
atory nature of this study, we do not provide further interpreta-
tions of this interaction. For the four remaining interactions, the
interaction appears to be due to significant effects of one genetic
variation only at certain levels of other genetic variation (Table 4).
Each of these interactions is further described below.
Among those with at least one PAI-1 5G allele, there is a
significantly lower hazard of cardiovascular disease associated with
the presence of each ACE D allele (For PAI-1 4G5G: adjusted
HR=0.74, 95% CI: 0.60–0.92; For PAI-1 5G5G: adjusted
HR=0.49, 95% CI: 0.32–0.75). For those with the PAI-1 4G4G
genotype, the effect of the ACE I/D polymorphism was in the
opposite direction, but not statistically significant (adjusted
HR=1.13, 95% CI: 0.79–1.62).
Among those with at least one ACE I allele, individuals with the
BDKRB2 C181T TT or BDKRB2 C181T CT genotypes had a
significantly higher hazard of cardiovascular disease as compared
to those who carried the BDKRB2 C181T CC genotype (adjusted
HR=1.77, 95% CI: 1.20–2.61). For those with the ACE DD
genotype, the effect of the BDKRB2 C181T polymorphism was in
the opposite direction, but was not statistically significant in the
adjusted model (although it was statistically significant in the
model unadjusted for covariates) (adjusted HR=0.52, 95% CI:
0.21–1.31).
For those with the AT1R A1166C AA genotype, individuals with
the BDKRB2 exon 1 I/D +9/+9 genotype had a significantly lower
hazard of cardiovascular disease as compared to those who carried
either the BDKRB2 exon 1 I/D 29/+9o r29/29 genotypes
(adjusted HR=0.45, 95% CI: 0.24–0.82). Among those with at
least one AT1R A1166C C allele, the effect of the BDKRB2 exon 1 I/
D polymorphism was in the opposite direction, but was not
statistically significant (adjusted HR=1.08, 95% CI: 0.66–1.76).
For those with the AT1R A1166C AA genotype, individuals with
the BDKRB2 C58T TT or BDKRB2 C58T CT genotypes had a
significantly higher hazard of cardiovascular disease as compared
to those who carried the BDKRB2 C58T CC genotype (adjusted
HR=1.67, 95% CI: 1.04–2.70). Among those with at least one
AT1R A1166C C allele, the effects of the BDKRB2 C58T
polymorphism were in the opposite direction, but not statistically
significant.
To assess whether the four significant gene-gene interactions
varied by sex, three-way interaction terms were added to each
model (sex x genotype1 x genotype2), along with the appropriate
lower order effects (i.e., the main effects plus the following two-way
interactions: genotype1 x genotype2, sex x genotype1, and sex x
Table 2. Univariate models for each polymorphism.
Dominant Model
1 Recessive Model
2
Additive model (linear
model)
3
Gene Polymorphism HR (P value) HR (P value) HR (P value)
BDKRB2 C181T (n=7,805) 1.12 (0.510) N/A N/A
BDKRB2 C58T (n=7,809) 0.94 (0.657) 1.11 (0.579) 1.00 (0.996)
BDKRB2 exon 1 I/D (n=7,728) 1.00 (0.986) 0.76 (0.132) 0.92 (0.377)
AT1R A1166C (n=7,675) 1.12 (0.443) 1.08 (0.760) 1.08 (0.458)
ACE I/D (n=7,405) 0.72 (0.042) 0.76 (0.114) 0.79 (0.029)
PAI-1 4G/5G (n=7,706) 0.87 (0.425) 0.88 (0.440) 0.90 (0.338)
1AA=0,Aa or aa=1.
2AA or Aa=0,aa=1.
3AA=0,Aa=1,aa=2.
For the correspondence of AA, Aa,a n daa to each genotype for each polymorphism, see Table 1.
doi:10.1371/journal.pone.0012757.t002
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way interactions were statistically significant at the 0.10 level of
significance in the unadjusted or adjusted models. However, for
the ACE I/D x PAI-1 4G/5G (additive-additive) interaction, the
three-way interaction was significant in the unadjusted (P=0.028)
and the adjusted models (P=0.028). Thus, sex may play a role in
the ACE I/D x PAI-1 4G/5G interaction. Preliminary examination
of the results suggests that the findings described earlier for the
ACE I/D x PAI-1 4G/5G interaction may be stronger for females
than for males. There was strong evidence of an ACE I/D x PAI-1
4G/5G interaction effect for females (adjusted P=0.001), while the
evidence was less convincing for males (adjusted P.0.10) (data not
shown). Subsequent research is necessary to validate this finding.
Discussion
Vascular fibrinolytic balance is maintained primarily by an
interplay of t-PA and PAI-1 [1] and polymorphisms in genes from
the RA, bradykinin, and fibrinolytic systems may affect plasma
concentrations of both t-PA and PAI-1 through a set of gene-gene
interactions [10,11], suggesting a potential involvement of these
systems in determining the risk of cardiovascular disease. The
present study suggests possible interactions between the ACE I/D
and PAI-1 4G/5G polymorphisms, the BDKRB2 C181T and ACE
I/D polymorphisms, the BDKRB2 exon 1 I/D and AT1R A1166C
polymorphisms, and the BDKRB2 C58T and AT1R A1166C
polymorphisms on the risk of cardiovascular disease. The
interaction between the ACE I/D and PAI-1 4G/5G polymor-
phisms appears to be robust to the choice of genotype coding
scheme. Interestingly, several of these interactions were noted in a
study of the epistatic effects of these polymorphisms on plasma t-
PA and PAI-1 levels [11]. Specifically, 5 out of the 6 interactions
noted in the present study were also found by Asselbergs et al. [11]
to be significant in the prediction of t-PA or PAI-1 in either males
or females – the exception is the BDKRB2 C181T x ACE I/D
interaction).
The association between ACE I/D and risk of cardiovascular
disease appears to be limited to those who carry the PAI-1 5G allele
and suggests a protective effect of the ACE D allele. While an
unexpected finding, a protective effect of ACE DD in the presence
of the PAI-1 5G allele is consistent with the multifactor
dimensionality reduction analysis findings of Coffey et al. [26].
In addition, other studies showed also a protective effect of the D
allele on the occurrence of thrombosis [27,28]. Interestingly, both
studies found that the effect was more pronounced in men
suggesting a gender interaction. Moreover, the absolute PAI-levels
were lower in the ACE DD group in the presence of PAI-1 5G5G,
which would be expected considering the observed protective
effect in the present study (data not shown). Although not
significant in the present study, there was a suggestion of increased
risk of the ACE D allele among those with the PAI-1 4G4G
genotype in the present study. This is consistent with previous
Table 3. Summary of the 16 significant interactions.
Interaction Covariate unadjusted Covariate adjusted
2
RAS-Fibrinolytic
ACE I/D x PAI-1 4G/5G
Additive-dominant P=0.060, AIC=5539.332 P=0.060, AIC=4536.416
dominant-additive P= =0.014, AIC=5536.024 P=0.015, AIC=4534.768
dominant-recessive P=0.046, AIC=5540.314 P=0.106, AIC=4541.769
dominant-dominant P=0.043, AIC=5539.895 P=0.015, AIC=4535.571
recessive-additive P=0.054, AIC=5543.344 P=0.117, AIC=4543.034
Additive-recessive P=0.011, AIC=5535.290 P=0.024, AIC=4535.330
recessive-recessive P=0.033, AIC=5543.093 P=0.038, AIC=4541.215
Additive-additive
1 P=0.007, AIC=5532.568 P=0.012, AIC=4531.608
AT1R A1166C x PAI-1 4G/5G
dominant-dominant
1 P=0.026, AIC=5759.063 P=0.151, AIC=4683.674
Bradykinin-RAS
BDKRB2 C181T x ACE I/D
dominant-additive P=0.079, AIC=5547.935 P=0.106, AIC=4541.118
dominant-recessive
1 P=0.015, AIC=5546.962 P=0.016, AIC=4539.052
BDKRB2 C58T x ACE I/D
recessive-dominant
1 P=0.093, AIC=5549.522 P=0.025, AIC=4544.774
BDKRB2 exon 1 I/D x AT1R A1166C
recessive-dominant
1 P=0.076, AIC=5635.521 P=0.028, AIC=4577.440
recessive-additive P=0.087, AIC=5635.938 P=0.017, AIC=4578.655
BDKRB2 C58T x AT1R A1166C
recessive-additive
1 P=0.020, AIC=5766.845 P=0.051, AIC=4686.709
recessive-recessive P=0.003, AIC=5768.088 P=0.015, AIC=4693.869
1Indicates most parsimonious model for the set of significant models within this pair of polymorphisms (model with lowest AIC among the covariate-adjusted models).
2Covariate-adjusted models are adjusted for sex, age, body mass index, presence of diabetes, systolic and diastolic blood pressure, HDL, total cholesterol, c-reactive
protein, current smoking status, and waist-to-hip ratio.
doi:10.1371/journal.pone.0012757.t003
CV Risk and SNP Interactions
PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12757basic science and human clinical studies. Both the ACE DD
genotype and the PAI-1 4G allele are associated with increased
PAI-1 levels [23,29,30], which promotes thrombosis and is a
known risk factor for myocardial infarction.
The other three interactions involve the bradykinin and RA
systems. Bradykinin plays an important role in determining t-PA
levels. In addition to its role in the inflammatory process,
bradykinin is a potent endothelial cell stimulant that has been
shown to induce the acute release of t-PA from the endothelium
through a B2 receptor mechanism [31]. In addition, ACE-
inhibition augments the effects of bradykinin on the B2 receptor,
which leads to t-PA release from the endothelium [32], providing a
mechanistic explanation for the interaction between the bradyki-
nin and RA systems. Moreover, genetic polymorphisms of the RAS
and bradykinin genes showed epistatic effects on both PAI-1 as t-PA
levels among females and males, similar to the results in the
current study.
Controlling for traditional risk factors of cardiovascular disease
did not lead to substantive changes in the results with respect to
statistical significance. However, this does not allow us to totally
rule out chance as a potential explanation of the findings.
Although there are plausible biologic mechanisms to support
interactions among genes from the RA, bradykinin, and
fibrinolytic systems, this study used an exploratory analysis plan
searching for all possible two-way interactions between six genes.
Furthermore, for each possible pair of polymorphisms, we tested
nine different interactions based on different genotype coding
schemes. Multiple tests increase the possibility of chance
associations, especially when conducting a non-replicated study.
Given that these tests are correlated in the present study, it is
difficult to calculate how many interactions are expected by
chance. However, by making some simplifying assumptions, and
noting that a total of 105 interactions were tested (nine possible
interaction effects were tested for the 15 possible pairs of
polymorphisms minus 30 interactions since only dominant coding
was used for the BDKRB2 C181T polymorphism), one can estimate
that under the null hypothesis, one would expect 2.6 and 10.5
interactions to be nominally significant at a=0.025 and a=0.10,
respectively, by chance alone (as described earlier, these are the
two uncorrected significance levels used in the present study). We
found a total of 16 significant gene-gene interactions (P,0.10),
most of which remained significant after adjusting for known risk
factors. The findings of significant interactions between genes from
the RA, bradykinin, and fibrinolytic systems on the risk of
cardiovascular disease warrant further exploration, including
attempting to replicate these results in other populations with
other study designs.
It is important to recognize that cardiovascular disease is a
relatively infrequent event in this cohort due to the young age
(mean 48.6 years at baseline) and gender composition (51%
female). The onset of symptoms is age related and additional
cardiovascular events are expected to be observed in the
PREVEND cohort as more time passes. In addition, the
penetrance of the alleles may also be age related. Future analyses
should examine whether these potential interactions remain as
additional events become available and the population grows
older.
Furthermore, because this study was limited to the investigation
of potential two-way interactions, future studies should consider
higher-order interactions using a multifactor dimensionality
reduction (MDR) type analysis [33,34]. Such analyses have
revealed the presence of gene-gene interactions in the absence of
statistically significant independent main effects and also may assist
in confirming the findings of the current exploratory study. Future
research should also explore the role of sex in moderating these
interactions. Finally, although this study was intended to evaluate
Table 4. Adjusted and unadjusted hazard ratios for incident CVD for given gene polymorphism at levels of another polymorphism.
Unadjusted HR Adjusted HR
1
Interaction (95% CI) P (95% CI) P
ACE I/D (additive
2)xPAI-1 4G/5G (additive)
ACE I/D at PAI-1 4G4G 1.18 (0.83–1.65) 0.360 1.13 (0.79–1.62) 0.506
ACE I/D at PAI-1 4G5G 0.78 (0.64–0.96) 0.018 0.74 (0.60–0.92) 0.008
ACE I/D at PAI-1 5G5G 0.52 (0.36–0.76) 0.001 0.49 (0.32–0.75) 0.001
BDKRB2 C181T (dominant) x ACE I/D (recessive)
BDKRB2 C181T (TT + CT versus CC)a tACE DD 0.41 (0.17–0.99) 0.049 0.52 (0.21–1.31) 0.165
BDKRB2 C181T (TT + CT versus CC)a tACE II or ACE ID 1.36 (0.93–1.99) 0.118 1.77 (1.20–2.61) 0.004
BDKRB2 C58T (recessive) x ACE I/D (dominant)
BDKRB2 C58T (TT versus CT + CC)a tACE II 1.64 (0.88–3.05) 0.118 2.23 (1.21–4.09) 0.010
BDKRB2 C58T (TT versus CT + CC)a tACE DD or ACE ID 0.85 (0.53–1.34) 0.477 0.92 (0.57–1.48) 0.717
BDKRB2 exon 1 I/D (recessive) x AT1R A1166C (dominant)
BDKRB2 exon 1 I/D (+9/+9 versus 29/+9 + 29/29) at AT1R A1166C AA 0.52 (0.30–0.90) 0.019 0.45 (0.24–0.82) 0.009
BDKRB2 exon 1 I/D (+9/+9v e r s u s29/+9 + 29/29) at AT1R A1166C CC or AT1R A1166C AC 1.01 (0.62–1.64) 0.967 1.08 (0.66–1.76) 0.770
BDKRB2 C58T (recessive) x AT1R A1166C (additive)
BDKRB2 C58T (TT versus CT + CC)a tAT1R A1166C AA 1.57 (1.00–2.46) 0.046 1.67 (1.04–2.70) 0.035
BDKRB2 C58T (TT versus CT + CC)a tAT1R A1166C AC 0.86 (0.56–1.33) 0.498 0.98 (0.64–1.52) 0.941
BDKRB2 C58T (TT versus CT + CC)a tAT1R A1166C CC 0.47 (0.21–1.08) 0.076 0.58 (0.25–1.35) 0.207
1Adjusted for sex, age, body mass index, presence of diabetes, systolic and diastolic blood pressure, HDL, total cholesterol, c-reactive protein, current smoking status,
and waist-to-hip ratio.
2Additive model coding for ACE I/D: II=0,ID=1,DD.
doi:10.1371/journal.pone.0012757.t004
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gene polymorphisms as diagnostic tools, it may be of some interest
to explore whether the significant gene-gene interactions found in
the present study can improve the predictive ability of known
models [35,36].
In summary, this study suggests possible interplay between
genes from the RA, bradykinin, and fibrinolytic systems on the risk
of cardiovascular disease, extending previous research that has
demonstrated that interactions among genes from these systems
influence plasma concentrations of both t-PA and PAI-1.
Supporting Information
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